Vicarious Surgical Inc
NYSE:RBOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vicarious Surgical Inc
NYSE:RBOT
|
US |
|
N
|
Novozymes A/S
SWB:NZM2
|
DK |
|
A
|
Agilent Technologies Inc
LSE:0HAV
|
US |
|
P
|
PLDT Inc
OTC:PHTCF
|
PH |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
US |
|
Golden Agri-Resources Ltd
SGX:E5H
|
SG |
|
Ormat Technologies Inc
NYSE:ORA
|
US |
|
MTAR Technologies Ltd
NSE:MTARTECH
|
IN |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
US |
|
Red River Bancshares Inc
NASDAQ:RRBI
|
US |
|
WiseTech Global Ltd
ASX:WTC
|
AU |
|
Vodafone Group PLC
LSE:VOD
|
UK |
|
Man Group PLC
LSE:EMG
|
UK |
|
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
UK |
|
Alaska Air Group Inc
NYSE:ALK
|
US |
|
Abionyx Pharma SA
PAR:ABNX
|
FR |
|
Eagle Eye Solutions Group PLC
LSE:EYE
|
UK |
|
Fomento Economico Mexicano SAB de CV
NYSE:FMX
|
MX |
|
Fission Uranium Corp
TSX:FCU
|
CA |
|
Monster Beverage Corp
NASDAQ:MNST
|
US |
|
Polski Koncern Naftowy Orlen SA
WSE:PKN
|
PL |
|
Elixirr International PLC
LSE:ELIX
|
UK |
|
Alps Alpine Co Ltd
TSE:6770
|
JP |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RBOT's stock price target?
Not Available
RBOT does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Vicarious Surgical Inc?
Projected CAGR
12%
The compound annual growth rate for Revenue over the next 4 years is 12%.